Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for BIOGY and 80,000+ other tickers.
See exactly how BIOGY's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for BIOGY and 80,000+ other tickers.
BioGaia AB (publ) is a global enterprise dedicated to the development, marketing, and sale of probiotic products, all backed by documented health benefits. The company organizes its activities into three primary divisions: Pediatrics, Adult Health, and 'Other'. Within the Pediatric segment, BioGaia provides items such as liquid drops, oral rehydration solutions, and gut health tablets, alongside supplying probiotic cultures for integration into infant formula. The Adult Health segment offers both digestive health tablets and oral hygiene lozenges, as well as providing cultures that are…
BioGaia AB (publ) (BIOGY) Q2 2026 Earnings Call Transcript
BioGaia AB (publ) (OTCPK:BIOGY) Q3 2025 Earnings Call October 22, 2025 3:30 AM EDT Company Participants Theresa Agnew - CEO & President Alexander Kotsinas - Executive VP & CFO Conference Call Participants Kristofer Liljeberg-Svensson - DNB Carnegie, Research Division Mattias Vadsten - SEB, Research Division Mattias Häggblom - Handelsbanken Capital Markets AB, Research Division Presentation Operator Welcome to BioGaia Q3 Report for 2025. [Operator Instructions] Now I will hand the conference over to CEO, Theresa Agnew; and CFO, Alexander Kotsinas.